Ikarian Capital’s Celldex Therapeutics CLDX Stock Holding History

Ikarian Capital’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.24M	Hold	114,000	–	–	0.46%	63
2026 Q1	$3.62M	Buy	+114,000	New	+$3.11M	0.29%	75
2025 Q2	–	Sell	-17,800	Closed	-$323K	–	146
2025 Q1	$323K	Sell	17,800 -187,700	-91%	-$4.19M	0.04%	128
2024 Q4	$5.19M	Sell	205,500 -100,000	-33%	-$2.72M	0.71%	40
2024 Q3	$10.4M	Buy	+305,500	New	+$11.6M	1.45%	18
2024 Q1	–	Sell	-200	Closed	-$7.93K	–	148
2023 Q4	$7.93K	Sell	200 -771	-79%	-$22.7K	﹤0.01%	134
2023 Q3	$2.67M	Buy	+971	New	+$30.4K	0.32%	71
2023 Q2	–	Sell	-110,000	Closed	-$3.96M	–	143
2023 Q1	$3.96M	Buy	+110,000	New	+$4.75M	0.9%	40
2022 Q3	–	Sell	-616,700	Closed	-$16.6M	–	121
2022 Q2	$16.6M	Buy	616,700 +21,200	+4%	+$616K	3.03%	6
2022 Q1	$20.3M	Buy	595,500 +144,300	+32%	+$4.61M	2.67%	9
2021 Q4	$17.4M	Sell	451,200 -69,000	-13%	-$3.01M	2.6%	7
2021 Q3	$28.1M	Buy	520,200 +504,200	+3,151%	+$23.7M	1.98%	11
2021 Q2	$535K	Buy	+16,000	New	+$439K	0.04%	185

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital's CLDX Position: Q2 2026 in Review

Ikarian Capital increased its Celldex Therapeutics (CLDX) stake by 3.7% in Q2 2026, buying an estimated $557K and bringing the position to 478,500 shares worth $17.8M. The position accounts for 1.92% of the portfolio, ranked #13.

Ikarian Capital first reported a position in CLDX in Q2 2020 and has held it in 14 quarters since. The position peaked at $23.9M in Q4 2020. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Ikarian Capital held 478,500 shares of Celldex Therapeutics worth $17.8M as of Q2 2026.
Ikarian Capital bought 17,253 Celldex Therapeutics shares in Q2 2026, an estimated $557K.
Celldex Therapeutics made up 1.92% of Ikarian Capital's portfolio in Q2 2026, its #13 holding.
Ikarian Capital first reported a position in Celldex Therapeutics in Q2 2020 and has held it in 14 quarters since.
Ikarian Capital's Celldex Therapeutics position peaked at $23.9M in Q4 2020.
254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.